Variant · Snv
DDR2 L239R
CI-VAR-00002313Explore in graph →ENST00000367922.3:c.716T>GClinVar 376141 CIViC 140
Curated evidence
Evidence by cancer (1 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22328973
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Lung Adenosquamous Carcinoma1 | ||||||||
| DDR2 L239R | Dasatinib | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID270The HCC-366 lung adenosquamous carcinoma cell line, containing the DDR2 L239R mutation was shown to be sensitive (IC50 140nm) to dasatinib in-vitro. The authors were unable to establish tumors using t… (full text at CIViC) PMID 22328973 · Hammerman et al., 2011 · Open in CIViC | civic |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available